Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Abbott AIDS Drug Didn't Make Patients Resistant to Others

From U.S. Centers for Disease Control and Prevention

February 8, 2001

A recent study shows that while about one-third of AIDS patients on Pfizer's Viracept medication developed resistance to protease inhibitors over 48 weeks, users of Abbott Laboratories' Kaletra drug did not become resistant. The results may indicate that Kaletra can be utilized as a first-line therapy for AIDS, says the University of Pittsburgh Medical Center's John W Mellors, and could be used more than once in treating HIV, both in early and later stages of the disease. Abbott's director of antiviral-drug development, Eugene Sun, does caution that virus mutations could eventually cause Kaletra users to develop protease inhibitor resistance.


Other CDC News for February 8, 2001

Namibian Government to Prosecute Healers

Study Reports Drug-Resistant Strains Have Increased to 14 Percent Among New HIV Cases

Bush to Retain AIDS Office; Corrects 'Mistake' by His Chief of Staff

Advertisement
Cipla AIDS-Drug Offer Changes Outlook

Abbott AIDS Drug Didn't Make Patients Resistant to Others 		In Study, Cycling AIDS Drugs On and Off Appears to Do No Harm

Belgian Firm Tests Drug Resistance of AIDS Patients

Trimeris' Good Problem: Test Results for AIDS Drug Mean More Competition

Detroit Promotes Safe Sex Week; High Levels of Disease Concerns Officials

UN Urges Malawi to Mount Vigorous War Against AIDS


Adapted from:
Wall Street Journal (www.wsj.com)
02/08/01 P. B13

  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
 
 

Advertisement